Mivacron
Executive Summary
Burroughs-Wellcome's short-acting neuromuscular blocker, mivacurium, was also scheduled to be discussed by FDA's Anesthetic and Life Support Drugs Advisory Committee on July 18. The company says the purpose of the meeting had been to discuss how FDA should review the NDA (No. 20-098). A meeting has not been rescheduled.